The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Ramalho de OliveiraDBrummelARMillerDB. Medication therapy management: 10 years of experience in a large integrated health care system. J Manag Care Pharm2010;16:185–195.
McKeeMFreiBLGarciaA. Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pract2011;17:387–394.
ManciniRWilsonD. A pharmacist managed oral chemotherapy program: an economic and clinical opportunity. Oncology Issues2012;(Januray/February):28–31.
HolleLMPuriSClementJM. Physician-pharmacist collaboration for oral chemotherapy monitoring: insights from an academic genitourinary oncology practice[published online ahead of print April 21 2015]. J Oncol Pharm Practpii: 1078155215581524.
WongSFBounthavongMNguyenC. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm2014;71:960–965.
AldridgeVEParkHKBounthavongMMorrealeAP. Implementing a comprehensive, 24-hour emergency department pharmacy program. Am J Health Syst Pharm2009;66:1943–1947.
DuganWMcDonaldMVPassikSD. Use of the Zung Self-Rating Depression Scale in cancer patients: feasibility as a screening tool. Psychooncology1998;7:483–493.
GoodinSGriffithNChenB. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract2011;7:7–12.
Safe Storage and Disposal of Cancer Medications. Available at: http://www.cancer.net/navigating-cancer-care/managing-your-care/safe-storage-and-disposal-cancer-medications. Accessed February 8 2016.
LeeAJBoroMSKnappKK. Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health Syst Pharm2002;59:2070–2077.
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed February 8 2016.
RaschettiRMorguttiMMenniti-IppolitoF. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol1999;54:959–963.
HowellACuzickJBaumM. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet2005;365:60–62.
PartridgeAHArcherLKornblithAB. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol2010;28:2418–2422.
KoppBJMrsanMErstadBLDubyJJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm2007;64:2483–2487.
BarnettMJFrankJWehringH. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years. J Manag Care Pharm2009;15:18–31.